IL157963A0 - Hsa-free formulations of interferon-beta - Google Patents

Hsa-free formulations of interferon-beta

Info

Publication number
IL157963A0
IL157963A0 IL15796301A IL15796301A IL157963A0 IL 157963 A0 IL157963 A0 IL 157963A0 IL 15796301 A IL15796301 A IL 15796301A IL 15796301 A IL15796301 A IL 15796301A IL 157963 A0 IL157963 A0 IL 157963A0
Authority
IL
Israel
Prior art keywords
beta
interferon
hsa
ifn
free formulations
Prior art date
Application number
IL15796301A
Other languages
English (en)
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27364838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL157963(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of IL157963A0 publication Critical patent/IL157963A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL15796301A 2001-04-09 2001-10-26 Hsa-free formulations of interferon-beta IL157963A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28261401P 2001-04-09 2001-04-09
US33040401P 2001-10-18 2001-10-18
US10/035,397 US6887462B2 (en) 2001-04-09 2001-10-25 HSA-free formulations of interferon-beta
PCT/US2001/051074 WO2002080976A2 (en) 2001-04-09 2001-10-26 Hsa-free formulations of interferon-beta

Publications (1)

Publication Number Publication Date
IL157963A0 true IL157963A0 (en) 2004-03-28

Family

ID=27364838

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15796301A IL157963A0 (en) 2001-04-09 2001-10-26 Hsa-free formulations of interferon-beta
IL157963A IL157963A (en) 2001-04-09 2003-09-17 HSA-free stabilized pharmaceutical formulation, method for increasing interferon beta solubility in pharmaceutical formulation and method for preparing hsa-free pharmaceutical preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL157963A IL157963A (en) 2001-04-09 2003-09-17 HSA-free stabilized pharmaceutical formulation, method for increasing interferon beta solubility in pharmaceutical formulation and method for preparing hsa-free pharmaceutical preparation

Country Status (19)

Country Link
US (5) US6887462B2 (el)
EP (3) EP2283896B1 (el)
JP (5) JP2004529917A (el)
KR (1) KR100900753B1 (el)
CN (1) CN1313148C (el)
AT (1) ATE545430T1 (el)
BG (1) BG66300B1 (el)
CA (2) CA2762966A1 (el)
CY (2) CY1113609T1 (el)
CZ (1) CZ305994B6 (el)
DK (1) DK1381432T3 (el)
ES (3) ES2453623T3 (el)
HU (1) HU228581B1 (el)
IL (2) IL157963A0 (el)
LU (1) LU92060I2 (el)
NO (1) NO330259B1 (el)
PL (1) PL213297B1 (el)
PT (2) PT1381432E (el)
WO (1) WO2002080976A2 (el)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE367828T1 (de) * 1998-04-03 2007-08-15 Novartis Vaccines & Diagnostic Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
US7544354B2 (en) 2000-10-27 2009-06-09 Novartis Vaccines And Diagnostics Methods of protein purification and recovery
JP4129178B2 (ja) * 2000-11-07 2008-08-06 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 安定化されたインターフェロン組成物
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
IL163577A0 (en) * 2002-03-12 2005-12-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
DE10240894A1 (de) * 2002-09-04 2004-03-11 Procom Biotechnologische Produktions Gmbh Verstärkung der Resorption von Subtanzen über die Haut und Schleimhaut
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP2006519170A (ja) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
WO2005042002A2 (en) * 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
CA2545458A1 (en) * 2003-11-10 2005-05-26 Arriva-Prometic Inc. Dry recombinant human alpha 1-antitrypsin formulation
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
ES2374530T3 (es) * 2003-12-11 2012-02-17 Ares Trading S.A. Formulaciones líquidas de interferón estabilizado.
CN1557479A (zh) * 2004-01-16 2004-12-29 深圳市海王英特龙生物技术股份有限公 干扰素脂质体乳膏
DE102004008168B4 (de) * 2004-02-19 2015-12-10 Voxeljet Ag Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung
JP2007526317A (ja) * 2004-03-01 2007-09-13 エンゾン ファーマスーティカルズ インコーポレイテッド インターフェロン−ベータ・ポリマー結合体
US20050220764A1 (en) * 2004-04-01 2005-10-06 Schering Aktiengesellschaft Higher-doses of interferon-beta for treatment of multiple sclerosis
CA2566364A1 (en) * 2004-05-17 2005-11-24 Ares Trading S.A. Hydrogel interferon formulations
KR101191536B1 (ko) * 2004-06-01 2012-10-15 아레스 트레이딩 에스.에이. 안정화된 인터페론 액상 제제
WO2005117949A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Stabilized interferon liquid formulations
ATE543506T1 (de) * 2004-06-01 2012-02-15 Ares Trading Sa Methode zur stabilisierung von proteinen
US20050276785A1 (en) * 2004-06-09 2005-12-15 Schering Aktiengesellschaft Treatment of cardiomyopathy and of endothelial dysfunction
JP2008507297A (ja) * 2004-07-26 2008-03-13 エンゾン ファーマシューティカルズ，インコーポレーテッド 最適化されたインターフェロンβ遺伝子
AU2005269527B2 (en) 2004-07-26 2011-12-01 Pfenex Inc. Process for improved protein expression by strain engineering
MX2007001663A (es) * 2004-08-12 2007-04-10 Schering Corp Formulacion de interferon pegilado estable.
PE20061416A1 (es) * 2005-05-19 2007-01-26 Schering Ag Sistema de expresion genetica que comprende un interferon-beta
US20060281703A1 (en) * 2005-05-19 2006-12-14 Schering Aktiengesellschaft Treatment of disease using an improved regulated expression system
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048848B2 (en) * 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
WO2007092252A2 (en) 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
CA2685326A1 (en) 2007-04-27 2008-11-06 Dow Global Technologies Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
KR101483814B1 (ko) 2007-09-04 2015-01-16 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
ATE548382T1 (de) * 2007-09-04 2012-03-15 Biosteed Gene Expression Tech Co Ltd Polyethylenglykolmodifiziertes interferon alpha 2b und herstellungsverfahren und anwendungen davon
EP2207890A4 (en) * 2007-10-05 2010-12-15 Barofold Inc HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS
JP5563475B2 (ja) * 2007-12-20 2014-07-30 メルク セローノ ソシエテ アノニム Ｐｅｇインターフェロン−ベータ製剤
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
US20100203014A1 (en) * 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
WO2010142017A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US9241897B2 (en) 2010-02-04 2016-01-26 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta
BR112013023062B1 (pt) * 2011-03-10 2022-01-18 Xeris Pharmaceuticals, Inc Solução estável para a injeção parenteral e método de fabricação da mesma
BR112014025951A2 (pt) 2012-04-19 2017-07-11 Opko Biologics Ltd variantes de oxintomodulina de longa ação e métodos de produção do mesmo
CN112661863A (zh) 2012-11-20 2021-04-16 奥普科生物制品有限公司 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2016052584A1 (ja) * 2014-09-30 2016-04-07 東レ株式会社 ポリエチレングリコール修飾インターフェロン－βの検出及び定量に使用する試料液の前処理方法、ポリエチレングリコール修飾インターフェロン－βの検出方法及び定量方法
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
EP3310347B1 (en) 2015-06-19 2021-08-04 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
FI126979B (en) * 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof
KR20240006077A (ko) 2016-07-11 2024-01-12 옵코 바이오로직스 리미티드 지속성 응고 인자 vii 및 그 제조 방법
MX2019001344A (es) 2016-08-02 2019-08-29 Ambah Ip Ltd Composicion inyectable estable de ibuprofeno.
KR101943160B1 (ko) * 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
US11690799B2 (en) 2018-04-19 2023-07-04 Lts Lohmann Therapie-Systeme Ag Microneedle system for applying interferon
CN112055582B (zh) * 2018-04-19 2023-09-29 Lts勒曼治疗系统股份公司 用于递送干扰素的微针系统
KR20240118230A (ko) * 2023-01-26 2024-08-05 에이비온 주식회사 인터페론 베타 건조 분말 제제 및 이의 제조방법

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
ES8308534A1 (es) 1980-01-08 1983-09-01 Biogen Nv Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos.
DE3005897A1 (de) 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
US4439181A (en) 1981-01-26 1984-03-27 Regents Of The University Of Minnesota Polyol-hormone mixture for use in chronic parenteral hormone administration
JPS5821691A (ja) 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
DE3273597D1 (en) 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
WO1983002461A1 (en) 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
AU1234383A (en) 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US5643566A (en) 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4462940A (en) 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US5702699A (en) 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
FI82266C (fi) 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4816400A (en) 1983-05-19 1989-03-28 Karl Tryggvason Basement membrane collagen degrading enzyme and method of purifying same
US4588584A (en) 1983-06-01 1986-05-13 The United States Of America As Represented By The Secretary Of Agriculture Medium for the isolation of Pseudomonas cepacia biotype from soil and the isolated biotype
GB8317880D0 (en) 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
DE3484374D1 (de) 1983-08-04 1991-05-08 Green Cross Corp Gamma-interferonzusammensetzung.
JPS6069037A (ja) 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
DE3482657D1 (de) 1983-11-21 1990-08-09 Univ Minnesota Gepuffertes polyol-hormones gemisch zur verwendung bei chronischer parenteraler hormonverabreichung.
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
GB8412564D0 (en) 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4605555A (en) 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4816440A (en) 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US4894330A (en) 1986-12-23 1990-01-16 Cetus Corporation Purification of recombinant beta-interferon incorporating RP-HPLC
EP0284249A1 (en) 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
US5151265A (en) 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
EP0410207B1 (en) 1989-07-24 1997-01-22 Bayer Corporation Stabilization of highly purified proteins
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5763566A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
EP0683890B1 (en) 1991-03-05 2002-04-03 Aradigm Corporation Method and device for correcting the drift offset of a pressure sensor of a flowmeter
DE69233690T2 (de) 1991-07-02 2008-01-24 Nektar Therapeutics, San Carlos Abgabevorrichtung für nebelförmige Medikamente
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
TW249202B (el) 1993-08-13 1995-06-11 Ciba Gerigy Corp
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5545723A (en) 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
FR2719479B1 (fr) 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5453433A (en) 1994-05-13 1995-09-26 Sterling Winthrop Inc. Thiadiazoles and antipicornaviral compositions
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
CA2190502A1 (en) 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
JP3706136B2 (ja) 1994-09-21 2005-10-12 ネクター セラピューティクス 乾燥粉末薬剤の分散装置及び方法
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
WO1998028007A1 (en) * 1996-12-24 1998-07-02 Biogen, Inc. Stable liquid interferon formulations
WO1998029141A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
JP4293497B2 (ja) 1997-09-23 2009-07-08 レントシュレール ビオテクノロジー ゲー・エム・ベー・ハー インターフェロン−β液状組成物
ATE367828T1 (de) 1998-04-03 2007-08-15 Novartis Vaccines & Diagnostic Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
EP2599503B1 (en) * 1998-10-16 2017-05-17 Biogen MA Inc. Polymer conjugates of interferon beta-1A and uses thereof
WO2001024814A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7544354B2 (en) 2000-10-27 2009-06-09 Novartis Vaccines And Diagnostics Methods of protein purification and recovery
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR034749A1 (es) 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano

Also Published As

Publication number Publication date
CN1313148C (zh) 2007-05-02
PL213297B1 (pl) 2013-02-28
EP2283897A3 (en) 2011-06-15
JP2008285499A (ja) 2008-11-27
EP2283896B1 (en) 2014-09-03
AU2002241769B2 (en) 2006-06-01
US7892531B2 (en) 2011-02-22
HUP0303732A2 (en) 2007-09-28
EP2283896A3 (en) 2011-05-25
IL157963A (en) 2013-08-29
EP1381432B9 (en) 2012-04-25
ES2524322T3 (es) 2014-12-05
EP2283896A2 (en) 2011-02-16
PT1381432E (pt) 2012-04-03
JP5701323B2 (ja) 2015-04-15
EP2283897A2 (en) 2011-02-16
US20050142110A1 (en) 2005-06-30
JP2015044882A (ja) 2015-03-12
CY1113609T1 (el) 2015-08-05
WO2002080976A3 (en) 2003-01-09
EP1381432A2 (en) 2004-01-21
NO20034492D0 (no) 2003-10-07
KR100900753B1 (ko) 2009-06-02
LU92060I9 (el) 2019-01-02
CZ305994B6 (cs) 2016-06-08
ATE545430T1 (de) 2012-03-15
BG108322A (bg) 2005-08-31
ES2367761T3 (es) 2012-05-04
PL366790A1 (en) 2005-02-07
NO330259B1 (no) 2011-03-14
EP1381432B1 (en) 2012-02-15
LU92060I2 (fr) 2012-10-15
US7371373B2 (en) 2008-05-13
HU228581B1 (en) 2013-04-29
BG66300B1 (bg) 2013-03-29
JP2013064020A (ja) 2013-04-11
DK1381432T3 (da) 2012-03-12
CY2012023I1 (el) 2015-08-05
US20040191219A1 (en) 2004-09-30
CN1511053A (zh) 2004-07-07
JP5580521B2 (ja) 2014-08-27
US6887462B2 (en) 2005-05-03
CA2442854A1 (en) 2002-10-17
ES2367761T1 (es) 2011-11-08
KR20030097825A (ko) 2003-12-31
US20110104116A1 (en) 2011-05-05
CY2012023I2 (el) 2015-08-05
US20020172661A1 (en) 2002-11-21
ES2453623T3 (es) 2014-04-08
JP2004529917A (ja) 2004-09-30
US8333958B2 (en) 2012-12-18
CA2442854C (en) 2012-03-13
JP2010018633A (ja) 2010-01-28
WO2002080976A2 (en) 2002-10-17
US20080193415A1 (en) 2008-08-14
EP2283897B1 (en) 2014-02-26
CZ20032735A3 (cs) 2005-03-16
NO20034492L (no) 2003-11-25
CA2762966A1 (en) 2002-10-17
PT2283896E (pt) 2014-12-16
US7399463B2 (en) 2008-07-15

Similar Documents

Publication Publication Date Title
IL157963A0 (en) Hsa-free formulations of interferon-beta
BR9808933A (pt) Composição sob forma de microcápsulas ou de implantes, processo de preparação de uma substância hidrossolúvel, substância ativa, acetato de triptorelina, acetato de lanreotìdeo, ou acetato de octreotìdeo, e rna de filamento duplo
ZA200501082B (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
CA2320182A1 (en) Compositions containing organic compounds
HUP0304082A3 (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0402179A3 (en) Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
HUP0204242A3 (en) Novel 1,3-dihydro-2h-indol-2-one derivatives, their preparation and pharmaceutical compositions compositions containing them
PL300194A1 (en) Interferon conjugate, method of obtaining same and pharmaceutical composition containing it
CA2189328A1 (en) Tocopherol compositions for delivery of biologically active agents
HUP0203542A3 (en) 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
WO2003002136A3 (en) Stable formulation of modified glp-1
IL188774A0 (en) Compositions for delivery of drug combinations
CA2366679A1 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
HUP0303118A3 (en) Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
EP1274443A4 (en) MICELLES
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
IL140140A0 (en) Thyroid hormone analogues and methods for their preparation
IL155788A (en) A highly purified ifn – β active and mannitol-containing preparation, a method to make an improved stability of ifn – β active, and a method to enhance the stability of ifn – β in biologically active formulation.
AP2004003045A0 (en) Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same.
IL184227A0 (en) Biologically active peptides
ZA978099B (en) Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance.
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
DE69900466D1 (de) Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen
GB0011734D0 (en) Pharmaceutical composition for anthelmintics (1)
HU0002156D0 (en) Novel piperazinyl alkylthio pyrimidinyl derivatives, pharmaceutical compositions containing such active ingredients and process for producing the active ingredients